Hepatic safety profile of elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV/HCV co-infected subjects in the STRATEGY switch trials

被引：0
|
作者：
Rashbaum, B. [1 ]
Lucasti, C. [2 ]
Mounzer, K. [3 ]
Melbourne, K. [4 ]
Kwon, P. [4 ]
Piontkowsky, D. [4 ]
机构：
[1] Capital Med Associates PC, Washington, DC USA
[2] South Jersey Infect Dis, Somers Point, NJ USA
[3] Philadelphia FIGHT, Philadelphia, PA USA
[4] Gilead Sci Inc, Foster City, CA 94404 USA
来源：
ANTIVIRAL THERAPY | 2014年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
P25
引用
收藏
页码：A44 / A45
页数：2
相关论文
共 50 条
  • [1] Resistance analyses of the elvitegravir/cobicistat/emtricitabine/tenofovir DF switch studies
    Andreatta, K.
    Kulkarni, R.
    Abram, M. E.
    Nguyen, T.
    Cao, H.
    Miller, M. D.
    White, K. L.
    ANTIVIRAL THERAPY, 2014, 19 : A144 - A144
  • [2] Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV patients with renal impairment
    Post, F.
    Andrade-Villanueva, J.
    Fisher, M.
    Winston, J.
    Liu, Y.
    Zhong, L.
    Cheng, A.
    Rhee, M.
    Szwarcberg, J.
    HIV MEDICINE, 2014, 15 : 115 - 115
  • [3] Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has non-inferior efficacy and favorable safety compared to efavirenz/emtricitabine/tenofovir DF in treatment naive HIV-1 infected subjects
    Sax, P.
    DeJesus, E.
    Mills, A.
    Zolopa, A.
    Cohen, C.
    Wohl, D.
    Gallant, J.
    Bosse, M.
    White, K.
    Liu, C.
    Plummer, A.
    Kearney, B.
    Quirk, E.
    Cheng, A.
    HIV MEDICINE, 2012, 13 : 9 - 9
  • [4] Reports of viral hepatitis B and C in HIV patients participating in clinical trials of elvitegravir/cobicistat/tenofovir DF/emtricitabine and cobicistat-boosted atazanavir plus tenofovir DF/emtricitabine
    Quirk, E.
    Graham, H.
    Liu, C.
    Rhee, M.
    Piontkowsky, D.
    Szwarcberg, J.
    ANTIVIRAL THERAPY, 2013, 18 : A63 - A63
  • [5] Evaluation of Safety and Effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch Followed by Ledipasvir/Sofosbuvir HCV Therapy in HIV-HCV Coinfection
    Doyle, Mary-Anne
    Lee, Terry
    Singer, Joel
    Crawley, Angela
    Klein, Marina
    Cooper, Curtis
    OPEN FORUM INFECTIOUS DISEASES, 2019, 6 (07):
  • [6] Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF in HIV-Infected Patients With Mild-to-Moderate Renal Impairment
    Post, Frank A.
    Winston, Jonathan
    Andrade-Villanueva, Jaime F.
    Fisher, Martin
    Liu, YaPei
    Beraud, Christophe
    Abram, Michael E.
    Graham, Hiba
    Rhee, Martin S.
    Cheng, Andrew K.
    Szwarcberg, Javier
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2015, 68 (03) : 310 - 313
  • [7] Efficacy and Safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF from an integrated analysis of Phase 2 and 3 clinical trials
    Fisher, M.
    Ward, D.
    Crowfoot, G.
    Shamblaw, D.
    Bellos, N.
    Chen, S.
    Rhee, M.
    Aizen, K.
    Szwarcberg, J.
    HIV MEDICINE, 2013, 14 : 55 - 55
  • [8] Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS
    Prinapori, Roberta
    Di Biagio, Antonio
    PATIENT PREFERENCE AND ADHERENCE, 2015, 9 : 1213 - 1218
  • [9] Week 96 efficacy and safety data: Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF in treatment-naive HIV-1-infected patients
    Orkin, C.
    Rockstroh, J.
    DeJesus, E.
    Henry, K.
    Molina, J.
    Gathe, J.
    Wei, X.
    Fordyce, M.
    Rhee, M.
    Smith, A.
    Szwarcberg, J.
    HIV MEDICINE, 2013, 14 : 56 - 56
  • [10] Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects
    Ramanathan, Srini
    Custodio, Joseph M.
    Wei, Xuelian
    Wang, Hui
    Fordyce, Marshall
    Dave, Ami
    Ling, Kah Hiing J.
    Szwarcberg, Javier
    Kearney, Brian P.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2016, 72 (03) : 281 - 288
12345